P2RY12 and myocardial infarction: The standard of care in patients undergoing PCI is dual antiplatelet therapy with a P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor) and aspirin to prevent major adverse cardiovascular events (MACE) such as death, stent thrombosis, myocardial infarction (MI), and stroke (8).